p53 is best known as a cell cycle regulator and an initiator of apoptosis and senescence. p53 dysfunction often leads to cancer; however, the relationship between p53 and oncogenesis goes beyond cell cycle dysregulation. In homeostatic conditions, p53 is a prominent immune regulator, from facilitating effector cell recognition to stimulating paracrine activity. As such, p53 mutations not only unshackle cancer cell proliferation, but also aid tumorigenesis, growth, and metastasis by impacting immune function in deleterious ways. Characterizing this immune function is essential in order to identify the unique superhero and supervillain cell subsets. IsoPlexis’ platform is able to identify these rare cell subsets which correlate to anti-tumor response or those contributing to disease progression, enabling and accelerating the development of curative medicines.
Download this poster from IsoPlexis to learn more about the p53-mediated pathways that impact immune system responses to cancer.
The Scientist c/o LabX Media Group
1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801
Toll Free: 888.788.0328 | Phone: 705.528.6888
Email: privacy@the-scientist.com
© 1986-2022 The Scientist
The Scientist needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.